Oxurion has announced the appointment of Professor Alan Stitt, PhD, as the company’s Chief Scientific Officer (CSO), effective January 19, 2021. This appointment follows the retirement of current CSO Jean Feyen, PhD, who has served in this position since joining the company in 2013. Dr. Feyen will remain available to the company during a transition period to support Professor Stitt and the rest of the preclinical development team.
Professor Stitt is the Chair of Experimental Ophthalmology at Queen’s University of Belfast and is internationally known for his research in ophthalmology, particularly in basic science relating to the pathogenesis of retinal diseases, especially diabetic retinopathy and age-related macular degeneration (AMD). He has also been awarded many accolades for his research including a Royal Society Merit Award, election to membership of the Royal Irish Academy (RIA) and Fellowship of the Association for Research in Vision & Ophthalmology (ARVO).
Beyond his research program, Professor Stitt contributes significantly to the international academic community by serving on advisory boards and grant panels and has a range of editor and editorial board memberships in the ophthalmology arena. Going forward, Professor Stitt will continue to perform his University duties and affiliations on a part time basis.
“I am excited to be joining Oxurion, a highly innovative company that I know well from my academic collaborations that have contributed to the selection and early development of THR-149 and THR-687,” Professor Stitt said in a company news release. “I look forward to working with their great team of scientists to help advance and broaden Oxurion’s highly promising pipeline. This comprises of novel drug candidates with differentiated modes of action targeting retinal disorders such as DME, but also dry AMD, for which there are currently no treatment options.”
“We are delighted to welcome Alan, with whom we have collaborated successfully for many years, to Oxurion to lead and direct our scientific research efforts. His successful research career in eye disease, extensive international network, and experience in translating science into clinical leads provide an ideal skill set to enhance our discovery and preclinical efforts,” Patrik De Haes, MD, CEO of Oxurion, said. “I look forward to working with Alan as our CSO as we pursue our mission to prevent vision loss and fight blindness worldwide by developing and delivering next generation treatments for key retinal disorders such as DME and dry AMD.”
“I would like to thank Jean for his leadership of the company’s preclinical development activities over the last several years which has been instrumental in building Oxurion’s success to date. We are grateful for his support during the transition and wish him well in his retirement,” Dr. Haes said.